Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Advertisement

Advertisement




Dec
20
Today In Oncology
NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer
Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns
Data Published on Incidence of Immune Checkpoint Inhibitor-Associated ITP
Lymphocyte Kinetics After CAR T Infusion Predict Survival Outcomes in Non-Hodgkin Lymphoma
CD123-Targeting ADC Shows Activity in AML and BPDCN
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo